-
![SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES](/abs-image/US/2015/08/13/US20150225405A1/abs.jpg.150x150.jpg)
公开(公告)号：US20150225405A1
公开(公告)日：2015-08-13
申请号：US14426369
申请日：2013-09-06
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Mallareddy Komandla , John David Lawson , Christopher McBride , Mingnam Tang
IPC: C07D487/04 , A61K31/4439 , A61K31/4985 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/4162 , C07D519/00
CPC classification number: C07D487/04 , A61K31/4162 , A61K31/437 , A61K31/4439 , A61K31/496 , A61K31/4985 , A61K31/506 , C07D487/14 , C07D519/00
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中L，R 1，R 2，R 3，R 4，R 5，R 6和R 7在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。
-
公开(公告)号：US10328089B2
公开(公告)日：2019-06-25
申请号：US15796519
申请日：2017-10-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , John David Lawson , Christopher McBride
IPC: A61K31/665 , A61K31/683 , A61K45/06 , C07F9/6558 , A61K31/66 , A61K38/28 , A61K31/155 , A61K31/192 , A61K31/216 , A61K31/336 , A61K31/397 , A61K31/4985 , A61K31/662 , A61P3/10 , A61K31/64
Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
公开(公告)号：US20160175332A1
公开(公告)日：2016-06-23
申请号：US14974033
申请日：2015-12-18
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , John David Lawson , Christopher McBride
IPC: A61K31/665 , C07F9/6558 , A61K31/683 , A61K45/06
CPC classification number: A61K31/665 , A61K31/155 , A61K31/192 , A61K31/216 , A61K31/336 , A61K31/397 , A61K31/4985 , A61K31/64 , A61K31/66 , A61K31/662 , A61K31/683 , A61K38/28 , A61K45/06 , A61P3/10 , C07F9/65586 , A61K2300/00
Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
Abstract translation: 公开了式1的化合物，其立体异构体和化合物和立体异构体的药学上可接受的盐，其中R1和R2在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。
-
Patent Agency Ranking
公开(公告)号：US20180050051A1
公开(公告)日：2018-02-22
申请号：US15796519
申请日：2017-10-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , John David Lawson , Christopher McBride
IPC: A61K31/665 , A61K31/66 , C07F9/6558 , A61K31/683 , A61K45/06
CPC classification number: A61K31/665 , A61K31/155 , A61K31/192 , A61K31/216 , A61K31/336 , A61K31/397 , A61K31/4985 , A61K31/64 , A61K31/66 , A61K31/662 , A61K31/683 , A61K38/28 , A61K45/06 , A61P3/10 , C07F9/65586 , A61K2300/00
Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
公开(公告)号：US09827255B2
公开(公告)日：2017-11-28
申请号：US14974033
申请日：2015-12-18
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , John David Lawson , Christopher McBride
IPC: A61K31/665 , A61K31/683 , C07F9/6558 , A61K31/66 , A61K45/06
CPC classification number: A61K31/665 , A61K31/155 , A61K31/192 , A61K31/216 , A61K31/336 , A61K31/397 , A61K31/4985 , A61K31/64 , A61K31/66 , A61K31/662 , A61K31/683 , A61K38/28 , A61K45/06 , A61P3/10 , C07F9/65586 , A61K2300/00
Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
![Substituted-1,4-dihydropyrazolo[4,3-b]indoles](/abs-image/US/2016/10/25/US09475816B2/abs.jpg.150x150.jpg)
公开(公告)号：US09475816B2
公开(公告)日：2016-10-25
申请号：US14426369
申请日：2013-09-06
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Mallareddy Komandla , John David Lawson , Christopher McBride , Mingnam Tang
IPC: C07D487/04 , C07D519/00 , A61K31/4439 , A61K31/4985 , A61K31/437 , A61K31/496 , C07D487/14 , A61K31/4162 , A61K31/506
CPC classification number: C07D487/04 , A61K31/4162 , A61K31/437 , A61K31/4439 , A61K31/496 , A61K31/4985 , A61K31/506 , C07D487/14 , C07D519/00
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
公开(公告)号：US09434743B2
公开(公告)日：2016-09-06
申请号：US14378305
申请日：2013-02-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Philip Erickson , Jun Feng , Mallareddy Komandla , John David Lawson , Christopher McBride , Joanne Miura , Sean Murphy , Mingnam Tang , Huong-Thu Ton-Nu
IPC: C07D498/04 , C07D401/04 , C07D471/04 , C07D403/04 , C07D405/04 , C07D417/04 , C07D487/04 , C07D401/14 , C07D413/14 , C07D231/56 , C07D403/10 , C07D407/14 , C07D413/04 , C07D413/10 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06
CPC classification number: C07D498/04 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D231/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D407/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
公开(公告)号：US20150005232A1
公开(公告)日：2015-01-01
申请号：US14378305
申请日：2013-02-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Philip Erickson , Jun Feng , Mallareddy Komandla , John David Lawson , Christopher McBride , Joanne Miura , Sean Murphy , Mingnam Tang , Huong-Thu Ton-Nu
IPC: C07D498/04 , A61K31/416 , A61K45/06 , C07D401/04 , A61K31/4439 , C07D471/04 , A61K31/437 , A61K31/5383 , C07D403/04 , A61K31/506 , C07D405/04 , C07D413/10 , A61K31/4245 , C07D417/04 , A61K31/427 , C07D401/14 , A61K31/5377 , C07D487/04 , A61K31/53 , C07D231/56
CPC classification number: C07D498/04 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D231/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D407/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
